POS1246 COVID-19 IN ITALIAN PATIENTS WITH RHEUMATIC AUTOIMMUNE SYSTEMIC DISEASES: RESULTS OF A NATIONWIDE SURVEY STUDY
Authors: C. Ferri, D. Giuggioli, V. Raimondo, L. Dagna, V. Riccieri, E. Zanatta, S. Guiducci, A. Tavoni, R. Foti, G. Cuomo, R. De Angelis, F. Cozzi, G. Murdaca, I. Cavazzana, N. Romeo, V. Codullo, F. Ingegnoli, R. Pellegrini, G. Varcasia, A. Della Rossa, M. De Santis, G. Abignano, M. Colaci, M. Caminiti, M. L’andolina, E. Lubrano, A. Spinella, F. Lumetti, G. De Luca, S. Bellando Randone, E. Visalli, S. Bilia, F. Masini, G. Pellegrino, E. Pigatto, E. Generali, F. Franceschini, G. Pagano Mariano, S. Barsotti, G. Pettiti, G. Zanframundo, R. Brittelli, V. Aiello, D. Scorpiniti, T. Ferrari, R. Caminiti, C. Campochiaro, P. Gigliotti, R. Cecchetti, D. Olivo, F. Ursini, V. Brusi, R. Meliconi, F. Caso, R. Scarpa, S. D’angelo, F. Iannone, M. Matucci-Cerinic, A. Doria, M. Miccoli, S. R. Paparo, F. Ragusa, G. Elia, S. M. Ferrari, P. Fallahi, A. Antonelli
Journal: Annals of the Rheumatic Diseases (2021)

Background: SARS-CoV-2 infection poses a serious challenge for patients with rheumatic autoimmune systemic diseases (ASD), characterized by marked immune-system dysregulation and frequent visceral organ involvement. Objectives: To evaluate the impact of Covid-19 pandemic in a large series of Italian patients with ASD. Methods: Our multicenter telephone survey (8-week period, March-April 2020) included a large series of 2,994 patients (584 M, 2,410 F, mean age 58.9±13.4SD years) with ASD followed at 34 tertiary referral centers of 14 regions of northern, central, and southern Italian macro areas, characterized by different prevalence of SARS-CoV-2 infection. According to currently used criteria, Covid-19 was classified as definite Covid-19 (signs or symptoms of Covid-19 confirmed by positive oral/nasopharyngeal swabs at PCR testing) or highly suspected Covid-19 (signs or symptoms highly suggestive of Covid-19, but not confirmed by PCR testing due to limited availability of virological tests in that period). The results were analyzed performing the Odds Ratio by Java-Stat 2-way Contingency Table Analysis. Results: The main findings of the survey study revealed a significantly increased prevalence of Covid-19 in: a.the whole series of ASD patients ( definite Covid-19: 22/2994, 0.73%; p=0.0007; definite Covid-19 plus highly suspected Covid-19: 74/2,994, 2.47%; p&lt;0.0001) when compared to Italian general population of Covid-19 infected individuals (349/100000 = 0.34%; data from Italian Superior Institute of Health; https://www.epicentro.iss.it/en/coronavirus/sars-cov-2-national-surveillance-system ). b.the subgroup of patients with connective tissue diseases or systemic vasculitis (n = 1,901) compared to the subgroup of inflammatory arthritis (n = 1,093), namely rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis ( definite Covid-19: 19/1,901, 0.99%, vs 3/1,093, 0.27%; p=0.036; definite Covid-19 plus highly suspected Covid-19: 69/1,901, 3.6%, vs 5/1,093, 0.45%; p&lt;0.0001) c.the subgroup of patients with pre-existing interstitial lung involvement (n = 526) compared to those without (n = 2,468) ( definite Covid-19: 10/526, 1.90%, vs 12/2,468, 0.48%; p=0.0015; definite Covid-19 plus highly suspected Covid-19: 33/526, 6.27%, vs 41/2,468, 1.66%; p&lt;0.0001). Of interest, the prevalence of Covid-19 did not correlate with presence/absence of different comorbidities, mainly diabetes, cardio-vascular and/or renal disorders, as well as of ongoing treatments with biological DMARDs; while patients treated with conventional DMARDs showed a significantly lower prevalence of Covid-19 compared to those without. Covid-19 was more frequently observed in the patients’ populations from northern and central compared to southern Italian macro area with lower diffusion of pandemic. Clinical manifestations of Covid-19, observed in 74 patients, were generally mild or moderate; 4/9 individuals requiring hospital admission died for severe pneumonia. Conclusion: The prevalence of Covid-19 observed in ASD patients during the first wave of pandemic was significantly higher than that observed in Italian general population; moreover, the actual prevalence of Covid-19 might be underestimated due to the high number of mild variants as well as the possible clinical overlapping between these two conditions. Patients with ASD should be invariably regarded as ‘frail patients’ during the pandemic course, considering the risk of worse outcome in the acute phase of Covid-19, as well as the potential long-term effects of viral infection. The statistically significant association of Covid-19 with connective tissue diseases/systemic vasculitis, as well as with pre-existing interstitial lung involvement, suggests the presence of distinct clinico-pathological ASD subsets, characterized by markedly different patients’ vulnerability to SARS-CoV-2 infection. Disclosure of Interests: None declared